Business Description
Regnum Corp
NAICS : 541713
SIC : 2834
Description
Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.3 | |||||
| Equity-to-Asset | -2.72 | |||||
| Debt-to-Equity | -1.16 | |||||
| Debt-to-EBITDA | -2.42 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -152 | |||||
| 3-Year EPS without NRI Growth Rate | -146.6 | |||||
| 3-Year FCF Growth Rate | -149.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 0.47 | |||||
| 9-Day RSI | 11.85 | |||||
| 14-Day RSI | 27.62 | |||||
| 6-1 Month Momentum % | -69.7 | |||||
| 12-1 Month Momentum % | -64.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.27 | |||||
| Quick Ratio | 0.27 | |||||
| Cash Ratio | 0.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.97 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -67.1 | |||||
| ROIC % | -41.97 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -3.48 | |||||
| EV-to-EBITDA | -3.48 | |||||
| EV-to-FCF | -2.4 | |||||
| Earnings Yield (Greenblatt) % | -28.74 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:RGMP
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Regnum Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.03 | ||
| Beta | -1.09 | ||
| Volatility % | 149.67 | ||
| 14-Day RSI | 27.62 | ||
| 14-Day ATR ($) | 0.009335 | ||
| 20-Day SMA ($) | 0.048205 | ||
| 12-1 Month Momentum % | -64.74 | ||
| 52-Week Range ($) | 0.0141 - 0.8 | ||
| Shares Outstanding (Mil) | 22.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regnum Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Regnum Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Regnum Corp Frequently Asked Questions
What is Regnum Corp(RGMP)'s stock price today?
The current price of RGMP is $0.01. The 52 week high of RGMP is $0.80 and 52 week low is $0.01.
When is next earnings date of Regnum Corp(RGMP)?
The next earnings date of Regnum Corp(RGMP) is .
Does Regnum Corp(RGMP) pay dividends? If so, how much?
Regnum Corp(RGMP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers